Recent Posts
Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement
This article was previously published by the Health and Human Rights Journal.
The scrambling for access to COVID-19 vaccines by developing countries has reignited the...
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...
Right to breathe takes precedence over company profits: Families of cystic fibrosis patients seek...
“Not even the doctors believed it would be so miraculous,” says 22-year old Rafaella Pereira. In two days, a new cystic fibrosis medicine took...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 22 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had harmed the Dutch healthcare system and the people who make use of it.
This work is licensed under